Insulin-producing cells injected into a man with type 1 diabetes have survived for a month so far without the need for immune ...

In type 2 diabetes, the body's ability to release insulin is impaired, which leads to high blood glucose levels. Research led ...

Sana Biotechnology has shared early data for its investigational allogeneic cell therapy being studied in one patient with ...

After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.

Doctors don’t know exactly what causes type 1 diabetes. For some reason, the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Genes may play a role in ...

Shares of Sana Biotechnology SANA skyrocketed 151.5% in the past week after the company announced positive initial results ...

Stanford Medicine researchers are using artificial intelligence to help identify the underlying biology behind Type 2 diabetes.

Sana Biotechnology (SANA) announced initial results from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic ...

During islet development, beta-cell death, rather than proliferation alone, regulates beta-cell mass and shapes the immune ...

First-in-Human Study Provides Evidence that Sana’s Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results ...

Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes ...

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...